Journal article
Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy
EG Findlay, AJ Currie, A Zhang, J Ovciarikova, L Young, H Stevens, BJ McHugh, M Canel, M Gray, SWF Milling, JDM Campbell, J Savill, A Serrels, DJ Davidson
Oncoimmunology | TAYLOR & FRANCIS INC | Published : 2019
Open access
Abstract
Immunization of patients with autologous, ex vivo matured dendritic cell (DC) preparations, in order to prime antitumor T-cell responses, is the focus of intense research. Despite progress and approval of clinical approaches, significant enhancement of these personalized immunotherapies is urgently needed to improve efficacy. We show that immunotherapeutic murine and human DC, generated in the presence of the antimicrobial host defense peptide LL-37, have dramatically enhanced expansion and differentiation of cells with key features of the critical CD103+/CD141+ DC subsets, including enhanced cross-presentation and co-stimulatory capacity, and upregulation of CCR7 with improved migratory cap..
View full abstractGrants
Awarded by University of Edinburgh
Funding Acknowledgements
This work was supported by the Royal Society [grant number DH150175] and Medical Research Council [grant number G1002046], [grant number G0802069].